51 results about "Colorectal cancer cell line" patented technology

The invention provides a colorectal carcinoma cell line CJF from hepatic metastasis and a construction method thereof. The obtaining method of the colorectal carcinoma cell line comprises the following steps: obtaining tissues of colorectal carcinoma hepatic metastasis; after digesting the tissues into single cells by using collagenase / hyaluronidase, separating and inoculating CD133+ cells under NOD (Non-Obese Diabetic) / SCID rat skin by MACS (magnetic-activated cell separation); nodulating, and taking out tumor tissues; and culturing in vitro to obtain the colorectal carcinoma cell line CJF which can stably passage and is rich in colorectal carcinoma stem cells. In the invention, CJF cells are obtained from hepatic metastasis of colonic carcinoma patients; compared with other colorectal carcinoma cell lines, the colorectal carcinoma cell line CJF has incomparable advantages for the study of the colonic carcinoma hepatic metastases; cell subsets of the CJF cells for stably expressing the CD133+ cells is about 10 percent; and the action and the research of the colorectal carcinoma cell line in a colorectal carcinoma hepatic metastases process and the tumor stem cells in a metastases mechanism have wide application prospects.

The present invention relates to the ferrocene derivative represented by formula (IA) or formula (IB), or to the pharmaceutically acceptable salt or solvate thereof and to the pharmaceutical composition thereof. Wherein, R is independently selected from H, halogen, cyano, nitro, C1-C6 alkyl, C1-C6 alkoxy, hydroxy-C1-C6 alkyl, halo-C1-C6 alkyl, halo-C1-C6 alkoxy or C1-C6 alkoxy-C1-C6 alkoxy; Z is selected from O, S or NR1, wherein R1 is independently H or C1-C6 alkyl; n is an integer from 0 to 5. The present invention also provides a method and the pharmaceutical application thereof for preparing the compounds represented by formula (IA) or formula (IB) or the pharmaceutically acceptable salts thereof. The compounds have a strong inhibitory activity against human lung cancer cell line A549, colorectal cancer cell line HCT116 and / or breast cancer cell line MCF-7.

The invention relates to a nicotinic acid derivative shown in the formula (I), and pharmaceutically acceptable salt or solvate thereof, wherein Z is selected from O, S and NR3, and R3 is hydrogen or C1-6 alkyl; R1 or R2 is independently selected from hydrogen, C1-6 alkyl, C1-6 alkoxy group, halogenated C1-6 alkyl, halogen, nitro, aryl, aryl oxygroup, heteroaryl, heteroaryl oxygroup, heterocyclic radical, and heterocyclic oxygroup; C1-6 alkoxy group, halogenated C1-6 alkyl, aryl, heteroaryl, and heterocyclic radical can be optionally substituted by substituent groups which can be C1-6 alkyl, C1-6 alkoxy group, halogenated C1-6 alkyl, halogen, cycano, nitro and aryl; m is an integer of 0 to 4; and n is an integer of 0 to 5. The compound or salts thereof have strong inhibition activity to colorectal cancer cell line HCT-116, human lung cancer cell line A549 and breast cancer cell line MCF-7. In addition, the compound is broad-spectrum in anti-cancer activity, and can be used as a candidate drug or a pilot compound for treating diseases of tumors, cancers and the like.

The invention discloses a mutated ubiquitin specific protease 33 gene and application of the mutated ubiquitin specific protease 33 (USP33) gene to production of a medicine for treating colorectal cancer. A research finds out that KDM5B has high expression in a colorectal cancer clinical sample and a colorectal cancer cell line and promotes the proliferation of colorectal cancer cells through inhibiting USP33. A KDM5B inhibitor or a monoclonal antibody of the KDM5B can be used for remarkably inhibiting the proliferation of the colorectal cancer cells. A further research proves that the KDM5B is combined with a USP33 gene promotor region, and the inhibition of the expression to the USP33 gene is realized through combining an upstream specific regulation and control sequence GCACA / C or G / TGTGC. The mutated ubiquitin specific protease 33 gene obtained through a site-directed mutation PCR (Polymerase Chain Reaction) technology can be used for resisting the inhibition effect of the KDM58B, so that the growth of the colorectal cancer cell line is inhibited.

The invention discloses a human colorectal cancer cetuximab drug-resistant cell line, and belongs to the field of biomedical technology. The human colorectal cancer cetuximab drug-resistant cell linehas the advantages that a human colorectal cancer cell line NCI-H508 is treated by the cetuximab of different concentration, and the drug concentration for survival of 50% of cells is used as the initial concentration to treat the cells for a long time, until the cell NCI-H508 can normally grow under the concentration; the cell NCI-H508 is continued to treat for a long time by a gradual increasingmethod, the treatment duration is six months, and finally the human colorectal cancer cetuximab drug-resistant cell line NCI-H508 / C225 which can quickly grow under the treatment function of the cetuximab can be finally obtained; the human colorectal cancer cetuximab drug-resistant cell line can be used for analyzing the phenotypic change of morphology and biology after drug resistance of human colorectal cancer cetuximab, studying the molecule mechanism of the human colorectal cancer cetuximab drug resistance and the reversing drug resistance method, screening other anti-tumor drugs, findingthe tumor drug-resistant markers, and screening and evaluating the novel antitumor drugs and the like, and the scientific and research value and the production and application value are higher.

The invention relates to an application of a natural compound 3-deoxysappanchalcone (3-DSC for short) in preparing medicine for inhibiting tumor cell proliferation. According to a cell proliferation experiment, the inhibiting effect of 3-DSC in a colorectal cancer cell line, especially in four cell lines: HCT-15, HCT-116, SW620 and DLD1 with highly expressed TOPK, is verified, therefore providing help and ground for clinically researching medicine for preventing and treating colorectal cancer.

MicroRNAs (miRNAs) are a class of small noncoding RNAs that have important regulatory roles in multicellular organisms. The public miRNA database contains 321 human miRNA sequences, 234 of which have been experimentally verified. To explore the possibility that additional miRNAs are present in the human genome, we have developed an experimental approach called miRNA serial analysis of gene expression (miRAGE) and used it to perform the largest experimental analysis of human miRNAs to date. Sequence analysis of 273,966 small RNA tags from human colorectal cells allowed us to identify 200 known mature miRNAs, 133 novel miRNA candidates, and 112 previously uncharacterized miRNA* forms. To aid in the evaluation of candidate miRNAs, we disrupted the Dicer locus in three human colorectal cancer cell lines and examined known and novel miRNAs in these cells. The miRNAs are useful to diagnose and treat cancers.

The invention provides a method for establishing a colorectal cancer animal model with an inflammation basis. The method includes the following steps that firstly, pBabe-CMV-EGFP-puro plasmids are established; secondly, a retrovirus-mediated EGFP overexpression system is established; thirdly, a colorectal cancer cell line stably expressing EGFP is established; fourthly, an axillary colorectal cancer transplanted tumor model of group A nude mice is established; fifthly, an inflammation model of group B nude mice is established; sixthly, the colorectal cancer animal model with the inflammation basis is established, wherein an axillary tumor of the group A nude mice is excised and sheared into tumor blocks with the diameter of 2 mm or so through sterile eye scissors, one tumor block is taken and directly sewn to the wall of the colorectum of the group B nude mice, the fifth step is repeated, feeding is carried out for one week, the fifth step is repeated again, feeding continues for one week, and the cancer animal model is obtained. With the animal model established through the method, the existence of tumors can be verified, and the size of tumors can be estimated.

A human-derived bradeion protein, which has the following properties: (i) it is a transmembranous protein; (ii) it has a structure characteristic of growth hormone and cytokine receptors even in a structure of its transmembranous portion when its structure is determined by a hydrophobicity analysis according to Kyte-Doolittle method; (iii) it is expressed at a high level in a human adult brain, and in less amount in the heart, while it is not expressed in other adult organs or fetus; (iv) it induces programmed cell death (apoptosis) when over-expressed in a cultured human nerve cell lines; (v) it induces termination of cell division and aging when over-expressed in a cultured human normal cell; (vi) it is located in cytoplasm, and forms an intracellular aggregate when overexpressed; and (vii) besides human adult neurons, it is specifically expressed in a human colorectal cancer cell line or in a skin cancer cell line, or an analogue thereof.

The invention discloses a new use of ipomoea batatas Sporamin protein. According to the invention, ipomoea batatas Sporamin protein can be applied to prepare products for preventing and / or treating tumours and preparing inhibitors for the proliferation of eukaryote tumour cells. Tests of anticancer activity show that ipomoea batatas Sporamin protein is able to inhibit the proliferation and metastasis of SW480 and HCT-8 cells in human colorectal cancer cell lines and Lewis lung cancer cells, and also inhibit the invasion of the cells to a basement membrane. Thus ipomoea batatas Sporamin protein has an obvious anticancer effect. In addition, deriving from grain crop ipomoea batatas, ipomoea batatas Sporamin protein enjoys high security which ensures the long-term medication of patients. And having essential aminoacid that is reasonable in composition, ipomoea batatas Sporamin protein plays a role in nutrition improvement and can improve the health of cancer patients from multiple perspectives.

The invention discloses a mutated ubiquitin specific protease 33 gene and application of the mutated ubiquitin specific protease 33 (USP33) gene to production of a medicine for treating colorectal cancer. A research finds out that KDM5B has high expression in a colorectal cancer clinical sample and a colorectal cancer cell line and promotes the proliferation of colorectal cancer cells through inhibiting USP33. A KDM5B inhibitor or a monoclonal antibody of the KDM5B can be used for remarkably inhibiting the proliferation of the colorectal cancer cells. A further research proves that the KDM5B is combined with a USP33 gene promotor region, and the inhibition of the expression to the USP33 gene is realized through combining an upstream specific regulation and control sequence GCACA / C or G / TGTGC. The mutated ubiquitin specific protease 33 gene obtained through a site-directed mutation PCR (Polymerase Chain Reaction) technology can be used for resisting the inhibition effect of the KDM58B, so that the growth of the colorectal cancer cell line is inhibited.

The present disclosure relates to a method for culturing colorectal cancer cell lines through organoid domestication, using organoid carriers and domestication medium to perform multiple domestication and culture of colorectal cancer single cells in colorectal cancer organoids, during the domestication culture process Gradually reducing the amount of organoid carrier used, the colorectal cancer single cells in colorectal cancer organoids gradually adapted to the two-dimensional culture environment, and were eventually domesticated into immortalized colorectal cancer cell lines. This disclosure creatively proposes a brand-new method for culturing colorectal cancer cell lines through organoid domestication, which can significantly shorten the establishment time of colorectal cancer cell lines and increase the success rate of colorectal cancer cell line establishment; in addition , the method has simple culture conditions and is easy to implement, and can establish human-derived colorectal cancer cell lines from primary cells in vitro with low cost and high efficiency.

The invention belongs to the field of chemical industry and medicine, and relates to 1-[N-(3,5-bis(2-(2-methoxyethoxy)ethoxy)ethoxy)benzyl-2,3,3-trimethyl bromide Application of salt dye (abbreviated as Cy5‑671) in the preparation of antitumor drugs. MTT results showed that Cy5‑671 could significantly inhibit the viability of colorectal cancer cell lines HCT116 and SW480. Animal experiment results show that: Cy5‑671 significantly inhibits the growth of human colorectal cancer cell line HCT116 BALB / C nude mice subcutaneously bearing tumors, and can be used to prepare antitumor drugs. The Cy5-671 of the present invention is developed as a new type of anti-tumor drug or its auxiliary components, and has a remarkable tumor-inhibiting effect, and will provide a new treatment approach and means for treating tumors.